ContraFect

Developing first-in-class therapies for drug resistant, life threatening infections.

[ContraFect @ContraFectCorp]

Focus on #exebacase PH3 & interim futility in July: also presented 2 posters @ASMicrobiology #ASM2022. $CFRX compiles data w/ potential to show utility of exebacase against #antibioticresistant staphylococcus in a variety of settings & our #DLA platform https://t.co/1qUUTpy6br

[ContraFect @ContraFectCorp]

$CFRX PH3 DISRUPT milestone! Exceeded 60% enrollment of #MRSA pts needed for #DSMB to progress w/ interim futility analysis & assess #exebacase superiority on primary efficacy endpoint. Data to DSMB early July. Incredible effort by CF team during pandemic. https://t.co/EMAgHuBQJQ

[ContraFect @ContraFectCorp]

DLA #CF370 center stage w/ #ECCMID2022 oral presentation. Data demonstrated⬆️efficacy in rabbit model of hard-to-treat extensively-drug-resistant strain of P. aeruginosa & CF-370 ability to avoid #AMR & suppress #antibioticresistance. Kudos to $CFRX team!
https://t.co/CHgO2l73Md

[ContraFect @ContraFectCorp]

Big lineup @ #ECCMID2022: $CFRX selected for oral presentation & six posters. New data will highlight lead candidate #exebacase in #PH3 superiority study, #CF370 our engineered lysin, & lead compounds in our amurin peptide program. See you live or online!
https://t.co/xh7XU7HsDo

[ContraFect @ContraFectCorp]

.@FrontiersIn Microbiology $CFRX team: #DLA primer on MOAs; potent activity against Gram➕ & Gram➖ bacteria. DLAs have rapid bactericidal & #antibiofilm activity, work w/antibiotics & low resistance = superior pt. response,⬇️ mortality &⬆️health economics
https://t.co/mpKYXCvcqE

[ContraFect @ContraFectCorp]

.@TheLancet global perspective on #AMR: BSI #2 in frequency of occurrence & 1 of 3 infections that lead to 78% of all AMR deaths. "In 2019 methicillin-resistant #Saureus was pathogen–drug combo w/100K+ deaths & 3.5M DALYs. #Exebacase on path to meet need.
https://t.co/G15oOco8x2

[ContraFect @ContraFectCorp]

NEWS: @CF_Foundation awarded $CFRX addtl. funding to investigate #exebacase to treat serious #MRSA lung infections for #CysticFibrosis. MRSA's prevalence in #cf grown - ⬆️9.2% in 2002 to 25.9% in 2017; major cause of lung function ⬇️ & mortality in CF pts.
https://t.co/8M6zIfJ0b4

[ContraFect @ContraFectCorp]

Clinical Infectious Diseases @IDSAInfo: $CFRX 1st #DLA #exebacase & peds MRSA; 5 mos. infant after evaluation @DukeU confirmed w/#MRSA & pt. could not clear w/SOC antibiotics; life-threatening. MD obtained emergency use to treat. Motivating, trials planned https://t.co/nUdLaEIqwV

[ContraFect @ContraFectCorp]

ICYMI: $CFRX CEO Dr. Pomerantz shares our Direct Lytic Agent #DLA approach @ the recent @Benzinga Small CAP Conference: "We are not an antibiotic company... if we are successful as we expect, it will change how you look at treating bacterial infections."
https://t.co/ZstnId3Gq1

[ContraFect @ContraFectCorp]

$CFRX presents @ North American Cystic Fibrosis Conference #NACFC 2021: our direct lytic agents demonstrate in vitro activity against prevalent #Gramneg pathogens & #multidrugresistant strains linked w/ pulmonary infections in #cysticfibrosis patients.
https://t.co/ldtSWcizAw

[ContraFect @ContraFectCorp]

Check out our $CFRX CEO interview: Roger Pomerantz discusses engineered lysins, #exebacase's role as new modality causing a paradigm shift as an #antimicrobial, & ContraFect's next candidate #CF370 targeting #PseudomonasAeruginosa. Great recap of our mission and clinical focus!

[BioTuesdays @BioTuesdays]

This weeks feature - In a bid to counter the next great health crisis, ContraFect is in late-stage development of a new modality to treat life-threatening and antibiotic-resistant infections, using direct lytic agents (DLAs). $CFRX https://t.co/Cn5qudFb7l

[ContraFect @ContraFectCorp]

$CFRX Late Breaker @#IDWeek2021 w/new PH2 data: rapid & meaningful symptom resolution when exebacase + standard of care antibiotics SOCA. ↓ time to response as well as ↑ response rates critical - staph aureus lead cause of infection in US HC facilities.
https://t.co/HdjrruyXxV

[ContraFect @ContraFectCorp]

ICYMI: CEO Roger Pomerantz talks $CFRX "trifecta" superiority vs SOC @ Cantor Global HC - #exebacase focus: clinical response, reduced mortality, & health economics critical in superiority & for anti-infective success. Partnerships w/ @BARDA & @pfizer key
https://t.co/6A74QntSs3

[ContraFect @ContraFectCorp]

$CFRX @IDWeek2021: will deliver late breaker oral presentation on rapid symptom resolution in adult pts w/Staph aureus bacteremia, treated w/#exebacase in completed Ph2, Dr. Cara Cassino, our CMO will present. Also poster on exebacase, Staph aureus & #MRSA https://t.co/8gOwaBlhVS

[ContraFect @ContraFectCorp]

ICYMI $CFRX data in Antimicrobial Agents & Chemotherapy @ASMicrobiology & Journal of Antimicrobial Chemotherapy @BSACandJAC #CF296 potent bactericidal & anti-biofilm against #StaphAureus; add CF-296 to daptomycin or vancomycin get stronger antibacterial
https://t.co/wKMgWbWXbZ

[ContraFect @ContraFectCorp]

New data @ESCMID #ECCMID2021: #exebacase, #PH3 w/ Breakthrough Therapy Designation for #MRSA, has potential to treat Staph bone & joint infections. #CF370 1st engineered lysin shows activity against #MultiDrugResistant #GramNeg. $CFRX programs move forward
https://t.co/1bo3h1Xxkn

[ContraFect @ContraFectCorp]

$CFRX presents new data #WorldMicrobeForum (@ASMicrobiology & @FEMSmicro) on #lysin & #amurin therapeutics 6/21-24. Deliver 2 oral presentations & 3 posters; demonstrate #CF370 activity, w/ other candidates, against #Gramneg pathogens. Register online! https://t.co/bj2zsyvIiv

[ContraFect @ContraFectCorp]

$CFRX builds senior team: appointed Gary Woodnutt PhD as SVP, Translational Sciences & Preclinical Development. Oversee strategy #earlystage assets & translational programs for #clinicaltrials. 30 yrs R&D exp. w/ innovative therapies. Welcome Gary!
https://t.co/Nbg1K2xXZ3

[Tristan Ferry @FerryLyon]

Arthroscopic “Debridement and Implant Retention” with local administration of #Exebacase (#phage #Lysin called CF-301 from @ContraFectCorp) @CrioacLyon @CHUdeLyon in 4 elderly patients with relapsing multiresistant S. epidermidis prosthetic knee infection https://t.co/t8YcjyNb5t

[ContraFect @ContraFectCorp]

Important IP news:@uspto issued $CFRX patent for #CF370, our 2nd potential therapeutic candidate. Patent titled Lysin-Antimicrobial Peptide (AMP) Polypeptide Constructs, Lysins, Isolated Polynucleotides, part of our #DLA portfolio, #Gramnegative infections
https://t.co/v7BcQB36dI